Current statuses of molecular targeted and immune checkpoint therapies in hepatocellular carcinoma.
Ontology highlight
ABSTRACT: Treatment of advanced hepatocellular carcinoma (HCC) still confronts great challenges due to high rate of therapeutic resistance. The emergence of systemic treatment with molecular targeted and immune checkpoint therapies has brought novel approaches towards patients with advanced HCC. However, sorafenib, as the first approved systemic treatment in 2007, only increased overall survival by three months in advanced HCC patients. Afterwards, little progress has been made for molecular targeted agents. Only four molecular drugs are empirically used in clinical practice. Lenvatinib acts as a first-line drug, whereas regorafenib, ramucirumab, and cabozantinib are defined as second-line drugs. Nevertheless, clinical findings reveal that overall survival remains unchanged. Albeit immunotherapy-bas
SUBMITTER: Kong D
PROVIDER: S-EPMC7269783 | biostudies-literature | 2020
REPOSITORIES: biostudies-literature
ACCESS DATA